← Open Payments lookup

NPI 1427178821: Open Payments

NPI 1427178821. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$154 in 8 payments from 6 companies in 2025. Trend: 2023 $1,093 · 2024 $1,641 · 2025 $154

Food & beverage: $154
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)2$38
Otsuka America Pharmaceutical, Inc.2$33
Alkermes, Inc.1$24
Janssen Pharmaceuticals, Inc1$23
Lundbeck LLC1$19
Vanda Pharmaceuticals Inc.1$17

Products named: CAPLYTA, REXULTI, ARISTADA, INVEGA, FANAPT, ABILIFY ASIMTUFII.